Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring exits for Alphabet, Novartis, Celgene and Taiho.

Lundbeck and Novo-backed nausea and vomiting therapy developer Acacia Pharma raised $49.6m in its initial global offering in Brussels.

The purchase data analytics platform, which is backed by Aimia and Fidelity Information Services, had raised almost $210m in venture financing.

The Xiaomi-affiliated smart wearable device maker has become the latest Chinese company to go public in the US, floating in the middle of its range.

The respiratory tract infection therapy developer, which counts Novartis and PureTech Health as investors, has closed its IPO at $97.8m.

The pruritus treatment developer, which counts Novo and Merck & Co as shareholders, has closed its initial public offering, its shares having almost doubled in price.

The immuno-oncology drug developer, which is backed by Celgene and GV, floated above its range and has since seen its share price rise 75%.

The Biogen-backed Duchenne muscular dystrophy drug developer saw its share price rise sharply after securing approximately $125m in its IPO.

LexinFintech, the instalment buying platform operator backed by Bertelsmann, JD.com and Taikang, had initially targeted $500m in the offering.